Hypera SA (HYPMY)
5.85
+0.06
(+1.04%)
USD |
OTCM |
May 17, 16:00
Hypera Price to Book Value: 1.586 for May 17, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.586 |
| May 16, 2024 | 1.570 |
| May 15, 2024 | 1.598 |
| May 14, 2024 | 1.605 |
| May 13, 2024 | 1.607 |
| May 10, 2024 | 1.58 |
| May 09, 2024 | 1.604 |
| May 08, 2024 | 1.608 |
| May 07, 2024 | 1.623 |
| May 06, 2024 | 1.600 |
| May 03, 2024 | 1.610 |
| May 02, 2024 | 1.556 |
| May 01, 2024 | 1.456 |
| April 30, 2024 | 1.635 |
| April 29, 2024 | 1.585 |
| April 26, 2024 | 1.434 |
| April 25, 2024 | 1.505 |
| April 24, 2024 | 1.475 |
| April 23, 2024 | 1.490 |
| April 22, 2024 | 1.553 |
| April 19, 2024 | 1.492 |
| April 18, 2024 | 1.477 |
| April 17, 2024 | 1.492 |
| April 16, 2024 | 1.539 |
| April 15, 2024 | 1.561 |
| Date | Value |
|---|---|
| April 12, 2024 | 1.633 |
| April 11, 2024 | 1.622 |
| April 10, 2024 | 1.652 |
| April 09, 2024 | 1.715 |
| April 08, 2024 | 1.681 |
| April 05, 2024 | 1.695 |
| April 04, 2024 | 1.779 |
| April 03, 2024 | 1.709 |
| April 02, 2024 | 1.730 |
| April 01, 2024 | 1.698 |
| March 31, 2024 | |
| March 28, 2024 | 1.788 |
| March 27, 2024 | 1.800 |
| March 26, 2024 | 1.816 |
| March 25, 2024 | 1.795 |
| March 22, 2024 | 1.812 |
| March 21, 2024 | 1.859 |
| March 20, 2024 | 1.821 |
| March 19, 2024 | 1.867 |
| March 18, 2024 | 1.820 |
| March 15, 2024 | 1.856 |
| March 14, 2024 | 1.752 |
| March 13, 2024 | 1.854 |
| March 12, 2024 | 1.829 |
| March 11, 2024 | 1.775 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.315
Minimum
Mar 24 2020
3.119
Maximum
Nov 01 2022
2.266
Average
2.262
Median
Aug 13 2021
Price to Book Value Benchmarks
| Raia Drogasil SA | 6.944 |
| CEL-SCI Corp | 4.808 |
| AIM ImmunoTech Inc | 2.107 |
| IGC Pharma Inc | 3.942 |
| NovaBay Pharmaceuticals Inc | -- |
Price to Book Value Related Metrics
| PE Ratio | 10.82 |
| PS Ratio | 2.291 |
| PEG Ratio | 2.021 |
| Price to Free Cash Flow | 10.29 |
| Price | 5.85 |
| Earnings Yield | 9.24% |
| Market Cap | 3.703B |
| PEGY Ratio | 1.092 |
| Operating PE Ratio | 7.238 |
| Normalized PE Ratio | 10.71 |